Breast Cancer Clinical Trials

Find Breast Cancer Clinical Trials Near You

Randomized Controlled Trial of Postmastectomy Hypofractionated Radiotherapy Versus Conventional Fractionated Radiotherapy in Breast Cancer Patients Undergoing Prosthetic Breast Reconstruction

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study investigates the safety and efficacy of hypofractionated radiotherapy (HFRT) versus conventional fractionated radiotherapy (CFRT) in breast cancer patients undergoing total mastectomy with prosthetic reconstruction. Study Design Population: Patients with high-risk breast cancer after mastectomy and immediate implant reconstruction. Intervention: HFRT Arm: 43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks). Control Arm: CFRT (50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks). Endpoints Primary: Reconstruction failure rate (e.g., implant removal, capsular contracture)

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Female, aged 18-75 years

• Karnofsky Performance Status ≥60

• Histopathologically confirmed invasive breast adenocarcinoma

• Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins

• pT3 or N2-3 disease; or pT1-2N1

• No distant metastasis

• Completed standard neoadjuvant/adjuvant chemotherapy cycles

• ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy

• Signed informed consent

Locations
Other Locations
China
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Xuran Zhao, MD
923791362@qq.com
86-13661135602
Backup
Yirui Zhai, MD
januarywind@163.com
86-18610168510
Time Frame
Start Date: 2026-03-27
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 506
Treatments
Experimental: HFRT group
43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
Other: CFRT group
50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
Related Therapeutic Areas
Sponsors
Leads: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

This content was sourced from clinicaltrials.gov